Category:

21 December 2021 – Race Oncology Limited (“Race”) is pleased to announce that its Share Purchase Plan (SPP) has closed heavily oversubscribed with $43.9m received in applications from 2,340 shareholders. In line with the terms of the SPP, $29.7m will…

Race Oncology CEO/MD Phil Lynch speaks to Matt Birney of the Bulls n’ Bears Report about Race’s latest results and outlook.

10 December 2021 – Race Oncology Limited (“Race”) is pleased to announce it has extended and expanded its collaborative cardio-protective research program for Zantrene® (bisantrene dihydrochloride) with eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov and Doan Ngo, at The University…

08 December 2021 – Race Oncology Limited (“Race”) is pleased to share additional interim results from the Zantrene® (bisantrene dihydrochloride) preclinical heart safety research program led by eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov and Doan Ngo, in collaboration with…